Abstract
Study Design
Prospective study.
Objectives
To prospectively evaluate bone allografts during spinal fusion surgery for 1) the rate of contamination as a result of perioperative preparation, and 2) the types of bacterial organisms that may be transmitted through the contaminated bone allograft.
Summary of Background Data
Bone allografts are routinely used to enhance spinal arthrodesis procedures. Ready availability and lack of donor site morbidity make them valuable alternatives to iliac crest bone grafts. Reports of disease transmission of such organisms as hepatitis C, the human immunodeficiency virus, and a variety of bacterial pathogens through allograft bone implants raise concerns for patient and practitioner safety.
Methods
Our study population consisted of 50 consecutive (20 male and 30 female) patients (mean age at surgery, 15 years; range, 3−51 years) undergoing spinal deformity correction from May 2010 through October 2010, by 1 surgeon at 1 institution. The mean operative time was 297 minutes (range, 81−444 minutes), and the most commonly fused spinal levels were T5 to L4. During the procedure, the researchers prospectively obtained intraoperative microbial culture swabs from a container with freeze-dried allograft and from an empty identical control container. Aerobic and anaerobic bacterial culture growth was assessed for 7 days postoperatively. Each patient was observed for 6 weeks after surgery to ascertain any evidence of surgical-site infection.
Results
Microbial cultures showed bacterial growth in 4 cases: 1 allograft specimen (day 4, very light Staphylococcus aureus) and 3 control specimens (day 3, very light Enterococcus; day 4, very light S aureus; and day 6, Propionibacterium acnes). No patient showed signs of infection in the perioperative or 6-week postoperative period.
Conclusions
Intraoperative allograft preparation is not a major source of bone allograft contamination during spinal surgery.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Delloye C, Cornu O, Druez V, et al. Bone allografts: what they can offer and what they cannot. J Bone Joint Surg Br 2007;89:574–9.
Greenwald AS, Boden SD, Goldberg VM, et al. Bone-graft substitutes: facts, fictions, and applications. J Bone Joint Surg Am 2001;83:98–103.
Centers for Disease Control and Prevention. Invasive Streptococcus pyogenes after allograft implantationdColorado, 2003. MMWR Morb Mortal Wkly Rep 2003;52:1173–6.
Conrad EU, Gretch DR, Obermeyer KR, et al. Transmission of the hepatitis-C virus by tissue transplantation. J Bone Joint Surg Am 1995;77:214–24.
Eggen BM, Nordbo SA. Transmission of HCV by organ transplantation. N Engl J Med 1992;326:410–1.
Carlson ER, Marx RE, Buck BE. The potential for HIV transmission through allogeneic bone: a review of risks and safety. Oral-Surg Oral Med Oral Pathol Oral Radiol Endod 1995;80:17–23.
Centers for Disease Control. Epidemiologic notes and reports transmission of HIV through bone transplantation: case report and public health recommendations. MMWR Morb Mortal Wkly Rep 1988;37:597–9.
Simonds RJ, Holmberg SD, Hurwitz RL, et al. Transmission of human immunodeficiency virus type 1 from a seronegative organ and tissue donor. N Engl J Med 1992;326:726–32.
Centers for Disease Control and Prevention. Update: allograft-associated bacterial infectionsdUnited States, 2002. MMWR Morb Mortal Wkly Rep 2002;51:207–10.
Kainer MA, Linden JV, Whaley DN, et al. Clostridium infections associated with musculoskeletal-tissue allografts. N Engl J Med 2004;350:2564–71.
Mroz TE, Joyce MJ, Steinmetz MP, et al. Musculoskeletal allograft risks and recalls in the United States. J Am Acad Orthop Surg 2008;16:559–65.
Mroz TE, Joyce MJ, Lieberman IH, et al. The use of allograft bone in spine surgery: is it safe? Spine J 2009;9:303–8.
Patel R, Trampuz A. Infections transmitted through musculoskeletaltissue allografts. N Engl J Med 2004;350:2544–6.
Joyce MJ. Safety and FDA regulations for musculoskeletal allografts: perspective of an orthopaedic surgeon. Clin Orthop Relat Res 2005;435:22–30.
Tomford WW. Transmission of disease through transplantation of musculoskeletal allografts. J Bone Joint Surg Am 1995;77:1742–54.
Deijkers RLM, Bloem RM, Petit PLC, et al. Contamination of bone allografts: analysis of incidence and predisposing factors. J Bone Joint Surg Br 1997;79:161–6.
Ibrahim T, Stafford H, Esler CN, et al. Cadaveric allograft microbiology. Int Orthop 2004;28:315–8.
Ireland L, Spelman D. Bacterial contamination of tissue allograftsd experiences of the donor tissue bank of Victoria. Cell Tissue Bank 2005;6:181–9.
United States Food and Drug Administration. Human tissue intended for transplantation: final rule. Fed Regist 1997;62:40429.
United States Food and Drug Administration. Current good tissue practice for human cell, tissue, and cellular and tissue-based product establishments; inspection and enforcement; final rule. Fed Regist 2004;69:68611–88.
United States Department of Health and Human Services. Guidance for industry: eligibility determination for donors of human cells, tissues, and cellular and tissue-based products (HCT/Ps). Available at http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/CellularandGeneTherapy/ucm078703.pdf. Accessed January 13, 2012.
Author information
Authors and Affiliations
Corresponding author
Additional information
Author disclosures: HH (none); AJ (none); KMK (consultancy for DePuy Spine, K2M; grants from DePuy Spine, K2M; stock/stock options from K2M; travel/accommodations/meeting expenses from DePuy Spine); PRN (none); AM (none); BES (none); MCA (none).
Rights and permissions
About this article
Cite this article
Hassanzadeh, H., Jain, A., Kebaish, K.M. et al. Prevalence of Allograft Contamination During Intraoperative Processing for Spinal Deformity Correction Surgery. Spine Deform 1, 348–351 (2013). https://doi.org/10.1016/j.jspd.2013.06.003
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1016/j.jspd.2013.06.003